Most people would be horrified if you told them that they require medicine to be injected into their eyes, but for an ophthalmology practice with retina specialists, intravenous injections are extremely common. However, with new medications, new modifiers, and prior authorization requirements, this can feel like navigating a minefield for billers and coders. If you are associated with retina billing, then you must already be aware of all these complexities.
A patient comes in for their monthly Eylea or Avastin shots; the injection takes roughly 2 minutes, and the claims spend the next few weeks fighting for their life in the payer’s adjudication system. This is a really strange problem to have. Intravenous injections have become routine ophthalmologic procedures these days. Medical conditions like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion together account for thousands of injections given in clinics all across the world every year.
Yet, billing processes have not adjusted to the volume. A significant percentage of denials in retina practices is not about the medical necessity. Instead, they come down to a mismatch between the procedure code, CPT 67028, and the drug code (J-code) sitting next to it on the same claim. So, here we are going to take a look at why retina billing conflicts keep happening and how you can actually prevent denied claims.
What Is CPT 67028 Actually Reporting?
There are different medications retina specialists use for intravenous injections, and new medications are emerging every new day. The HCPCS Level II codes differ and change frequently. However, the CPT code for administering the drug remains the same. This is the CPT 67028 code, the code for intravenous injection of a pharmacology agent. This code comes with different modifiers.
If the patients need injection bilaterally, some doctors prefer to do each eye on a separate day. In this case, or in the event where the patient receives the injection in one eye, it is important to append the corresponding modifier LT (left) or RT (right) to the injection code during retina billing. If the physician performs bilateral injections in a single visit, the Modifier 50 bilateral procedure will have to be appended to the injection code.
When appending a bilateral modifier, the biller will have to invoice only one unit. The modifier already indicates to the payer that the treatment was done on two distinct body parts. This increases the chance of reimbursement. However, the CPT 67028 code only tells half the story. It says an injection has been given. However, it does not say anything about what actually was injected. That’s the J-code’s job, and this is exactly where the friction starts.
What Does the J-Code Signify?
Every anti-VEGF drug on the market comes with its own HCPCS J-code, and the differences between the J-codes are not cosmetic. Here are most of the commonly used J-codes in retina billing services:
- J0178: Aflibercept 1 mg (Eylea)
- J0177: Aflibercept 8 mg (Eylea HD)
- J2778: Ranibizumab 0.1 mg (Lucentis)
- J3398: Faricimab-svoa 6 mg (Vabysmo)
- J2781: Pegcetacoplan 1 mg (Syfovre, for geographic atrophy)
- J2782: Avacincaptad pegol 0.1 mg (Izervay, also for geographic atrophy)
- J9035: Bevacizumab 10 mg (Avastin, used off-label in ophthalmology)
These codes will have to be applied appropriately with the CPT code for the claim to be reimbursed without any issue.
What Happens When the Two Codes Don’t Match?
Each of the J-codes mentioned above only pairs cleanly with certain diagnostic codes, unit calculations, and certain payer coverage policies. When any of these aspects don’t line up with the 67028 line, the claim gets denied. According to the American Academy of Ophthalmology’s coding guidance for injectable drugs, the National Drug Code (NDC) will have to accompany the J-code on the claim, formatted in the 11-digit 5-4-2 sequence rather than the 10-digit format printed on the vial. In case that formatting is done wrong or the NDC is left off entirely, payers will kick the claim back before a human even looks at the clinical documentation.
Unit counting also comes with multiple challenges. J-codes are mostly billed against the dosage described in the code itself and not the volume in the syringe. If you bill 1 unit too many times or round off the 1 mg dose the wrong way, that means you have created a mismatch that has nothing to do with whether the patient actually needed the drug. For instance, the FDA-approved dose for wet AMD and DME is 2 mg. So, a correctly billed claim should show 2 units, according to the CMS Local Coverage Article for Aflibercept. If you bill 1 unit instead of 2, you’ve under-billed the drug cost. If you bill 4 because you know that the vial size equals the unit count, then it will result in an overpayment flag that can lead to a post-payment audit.
Then there’s the challenge associated with the Medically Unlikely Edit for retina billing. CMS caps CPT 67028 at one unit per eye per day. That may sound normal until a patient needs treatment for both wet AMD and geographic atrophy in the same eye on the same visit. The MUE only allows one injection to be paid, according to the AAO’s guidance on coding for geographic atrophy injections. Retina practices that lack this knowledge end up appealing a denial they could have avoided by scheduling the second injection outside the 28-day window in the first place.
Challenges in Using the Right Modifier in the Right Place
CPT 67028 does not have the ability to distinguish laterality on its own. So, every claim would require an -RT, -LT, or -50 modifier, and pears are often inconsistent about which they accept for a bilateral same-day injection. Some payers require two separate claim lines with the -RT and -LT modifiers, while others want a single line with the 50 modifier. Guessing this wrong often becomes the cause of retina billing claim rejection, as Retina Today has documented in its reviews.
Drug wastage may lead to another challenge. In July 2023, CMS required modifier JW for documented disregarded drug and modifier JZ to confirm that there was no wastage on a single-use vial. If you miss the JZ modifier on a clean no-waste claim, some payer will deny it rather than assuming it to be zero waste. This can again lead to a conflict if there is no challenge associated with the treatment that was offered to the patient.
Also, when an office visit happens on the same day as the injection, modifier 25 only belongs there if there is a separate genuine medical necessity and not because the physician glanced at the eye before administering the drug. Payers audit the modifier specifically since 67028 already bundles a brief pre-injection assessment.
Why Do These Challenges Keep Costing Practices Money?
While none of the challenges associated with retina billing are complicated in isolation, the trouble happens when a single injection claim requires different codes and modifiers to stack together. One weak link anywhere in that chain, and the whole claim comes back.
For retina practices running dozens of injections part-time, that denied claims add up fast, not just in real money but in staff time spent tracking down the mistakes and correcting them. That’s how revenue leakage occurs gradually. It does not show up as one big loss but as a gradual loss of money that is hard to detect until you are looking at an aging report.
This highlights the need for you to keep an eye on the revenue cycles. This will help you in catching the conflicts before claim submission. RCM Workshop can help ophthalmology practices with exactly this kind of payer-specific nuance. With their considerable experience in healthcare revenue cycle management, RCM Workshop can help practices send out clean claims and get reimbursements faster.
Tips To Reduce Claim Denials
Now here are some of the habits that you can follow in order to reduce chances of denial:
- Keep an up-to-date cheat sheet of J-codes and their matching NDCs for every drug in the injection formulary.
- Double-check unit math against the J-code’s dosage descriptor before the claim goes out.
- Confirm which modifier format the payer actually wants for bilateral same-day injections.
- Apply JW or JZ on every single-use vial claim, without exception.
- Flag same-day E/M codes for a documentation check before modifier 25 gets attached.
In Conclusion
So, as you can see, CPT 67028 and J-code are supposed to work as a pair in retina billing. However, payer systems are treating them as two different checkpoints a claim has to clear before being reimbursed. Understanding where those checkpoints are diverse is what separates a retina practice with a smooth revenue cycle from one that is constantly dealing with appeals. The clinical side of intravenous therapy has become exceedingly advanced over the years. So, you need to make sure that the billing side is also at pace to ensure smooth operations.
Want to streamline your ophthalmology billing practices? RCM Workshop can help.
